CalciMedica, Inc. (CALC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. A. Rachel Leheny Ph.D. | CEO & Director | 416.94k | -- | 1963 |
| Mr. Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board | 390.6k | -- | 1964 |
| Dr. Sudarshan Hebbar M.D. | Chief Medical Officer | 424.9k | -- | 1965 |
| Mr. Michael J. Dunn B.A., M.B.A. | President & COO | -- | -- | 1956 |
| Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor | -- | -- | -- |
| Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor | -- | -- | -- |
| Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor | -- | -- | -- |
| Dr. Kenneth A. Stauderman Ph.D. | Co-Founder & Chief Scientific Officer | 615.59k | -- | 1953 |
| Mr. Stephen B. Bardin | Chief Financial Officer | -- | -- | 1991 |
| Mr. John M. Dunn J.D. | General Counsel | -- | -- | 1952 |
CalciMedica, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California.
Corporate Governance
Upcoming Events
August 11, 2025 at 8:00 PM UTC - August 15, 2025 at 8:00 PM UTC
CalciMedica, Inc. Earnings Date